Exhibit 99.1
Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Phase 1/2 clinical trial enrolling for lead investigational candidate SNS-101, a conditionally active
VISTA-
blocking antibody for the treatment of advanced solid tumors
A total of 6 patients in three dosing cohorts enrolled to date, with initiation of combination arm now
planned for Q4 2023
Initial PK and safety data now expected by year-end 2023, and topline efficacy and biomarker data
expected in 2024
Strong balance sheet with cash runway into the second half of 2025
BOSTON, MA August 3, 2023 Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company
focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter ended June 30, 2023, and provided recent business updates.
The second quarter of 2023 was momentous for Sensei as we moved expeditiously from the FDAs clearance of our
SNS-101 trial in April to the enrollment of six patients by the end of July. Were encouraged by the rapid clinical enrollment activity weve observed so far, which suggests that we may be able to
accelerate the start of the combination arm of this study, said John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics. Were grateful for the efforts of the clinical investigators, patients, and families
without whom this clinical trial would not be possible.
Highlights and Milestones
SNS-101
Senseis lead investigational candidate is SNS-101, a conditionally active antibody targeting the immune
checkpoint VISTA (V-domain Ig suppressor of T cell activation), which is implicated in numerous cancer indications and whose expression correlates with low survival rates.
Recent updates for SNS-101 include:
|
|
|
An Investigational New Drug (IND) application for
SNS-101 was cleared by the U.S. Food and Drug Administration (FDA) in April 2023. The cleared starting dose of 0.3 mg/kg was substantially higher than other anti-VISTA antibodies.
|
|
|
|
On June 1, 2023, Sensei reported the first patient dosed in the dose escalation portion of
the SNS-101 multi-center Phase 1/2 clinical trial. To date, Sensei has enrolled a total of 6 patients, clearing its first patient cohort at 0.3 mg/kg and its second patient cohort at 1.0 mg/kg, and is
currently dosing patients in its third cohort at 3.0 mg/kg.
|
|
|
|
As a result of the pace of enrollment to date, Sensei expects to dose the first patient in combination with
Regenerons PD-1 inhibitor Libtayo® (cemiplimab) in Q4 2023. |